Pfizer India Launches Two Drugs With Hemas In Sri Lanka
This article was originally published in PharmAsia News
Executive Summary
Pfizer's India arm is launching a pair of drugs in Sri Lanka, one for treating cancer, the other inflammatory disorders, using Hemas Pharmaceuticals as prime distributor. Pfizer India's Managing Director Kewal Handa said the launch is part of the firm's plans to increase its Sri Lanka business, with several more key therapeutic drugs to be launched over the next three years. The two drugs leading the way are Pfizer India's Sutent (sunitinib) for life-threatening cancers and Medrol (methylprednisolone) for use when inflammatory disorders do not respond to conventional drugs satisfactorily. (Click here for more